thiazoles has been researched along with fidaxomicin in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dang, MD; DuPont, HL; Garey, KW; Hasbun, R; Jiang, ZD; Koo, HL; Shah, D | 1 |
| Johnson, AP | 1 |
| Bookstaver, PB; Miller, AD; Musgrave, CR; Sutton, SS | 1 |
| Citron, DM; Goldstein, EJ; Merriam, CV; Tyrrell, KL | 1 |
| Ballard, TE; Guerrant, RL; Hoffman, PS; Kennedy, A; Kolling, GL; Macdonald, TL; Olekhnovich, I; Riggins, M; van Opstal, E; Wang, X; Warren, CA; Warthan, M | 1 |
| Guerrant, RL; Hoffman, PS; Kolling, GL; Li, Y; Moore, JH; Riggins, MS; van Opstal, EJ; Warren, CA | 1 |
| Bauer, MP; Debast, SB; Kuijper, EJ; Sanders, IM; Wilcox, MH | 1 |
| Barnes, SW; Leeds, JA; Mullin, S; Ruzin, A; Sachdeva, M | 1 |
| Leeds, JA; Sachdeva, M | 1 |
| Johnson, S; Soriano, MM | 1 |
| Leeds, JA | 1 |
5 review(s) available for thiazoles and fidaxomicin
| Article | Year |
|---|---|
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Clostridioides difficile; Clostridium Infections; Drug Resistance, Bacterial; Fidaxomicin; Humans; Microbial Sensitivity Tests; Nitro Compounds; Randomized Controlled Trials as Topic; Rifamycins; Rifaximin; Thiazoles; Treatment Outcome | 2010 |
New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile.
Topics: Aminoglycosides; Anti-Bacterial Agents; Benzopyrans; Clostridioides difficile; Enterocolitis, Pseudomembranous; Fidaxomicin; Glycopeptides; Humans; Lipoglycopeptides; Nitro Compounds; Thiazoles; Thiophenes | 2010 |
Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection.
Topics: Aminoglycosides; Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Immunotherapy; Nitro Compounds; Polymers; Probiotics; Thiazoles | 2011 |
Treatment of Clostridium difficile infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Drug Administration Schedule; Drug Therapy, Combination; Fidaxomicin; Gastrointestinal Diseases; Humans; Metronidazole; Nitro Compounds; Randomized Controlled Trials as Topic; Recurrence; Rifamycins; Rifaximin; Thiazoles; Vancomycin | 2015 |
Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Clostridioides difficile; Clostridium Infections; Drug Resistance, Bacterial; Fidaxomicin; Genotype; Humans; Microbial Sensitivity Tests; Mutation; Thiazoles | 2016 |
6 other study(ies) available for thiazoles and fidaxomicin
| Article | Year |
|---|---|
Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Clostridioides difficile; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Intestines; Microbial Sensitivity Tests; Microbial Viability; Peptide Elongation Factor Tu; Protein Biosynthesis; Species Specificity; Thiazoles | 2012 |
Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Benzamides; Clostridioides difficile; Clostridium Infections; Disease Models, Animal; Enzyme Inhibitors; Fidaxomicin; Mice; Microbial Sensitivity Tests; Nitro Compounds; Pyruvate Synthase; Thiazoles; Treatment Outcome; Vancomycin | 2012 |
Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Bacteroides; Cecum; Clostridioides difficile; Clostridium Infections; DNA, Bacterial; Enterocolitis, Pseudomembranous; Feces; Fidaxomicin; Intestines; Male; Metronidazole; Mice; Mice, Inbred C57BL; Nitro Compounds; Recurrence; Thiazoles; Treatment Outcome; Vancomycin | 2013 |
Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cross Infection; Enterocolitis, Pseudomembranous; Europe; Fidaxomicin; Humans; Metronidazole; Microbial Sensitivity Tests; Multilocus Sequence Typing; Polymerase Chain Reaction; Ribotyping; Thiazoles; Treatment Outcome; Vancomycin | 2013 |
In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cell Wall; Clostridioides difficile; DNA Mutational Analysis; DNA-Directed RNA Polymerases; DNA, Bacterial; Drug Resistance, Bacterial; Fidaxomicin; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Selection, Genetic; Sequence Analysis, DNA; Serial Passage; Thiazoles; Vancomycin | 2014 |
Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile.
Topics: Aminoglycosides; Clostridioides difficile; Fidaxomicin; Metronidazole; Microbial Sensitivity Tests; Thiazoles; Vancomycin | 2015 |